Browse by Audience
MEMBER

Update Your Profile
Member Spotlights
Refer a Member: IASP Champions
Join a Special Interest Group (SIG)
Find a Chapter
Join Now

RESEARCHER

PAIN
PAIN Reports
Pain Research Forum
Papers of the Week
Webinars and Podcasts
Events

HEALTH CARE PROVIDER

Online Learning - PERC
Webinars & Podcasts
Curricula
Graduate Opportunities
Events

PATIENT & CAREGIVER

RELIEF News
Resources for Living with Pain
Global Alliance of Partners in Pain Advocacy (GAPPA)
Events

PARTNER

Support IASP
Sponsor an Event
Become a Partner

gy2022-1-3
I am a
IASP Logo
Home I AM A Search Login

Papers of the Week

Home / Publications / Pain Research Forum / Papers of the Week / Predictors of Sustained Response and Effects of Anti-CGRP Antibodies Discontinuation and Reinitiation in Resistant Chronic Migraine.

< BACK TO ARCHIVE


Papers: 29 Jan 2022 - 4 Feb 2022


Human Studies


2022 Jan 31


Eur J Neurol


http://www.ncbi.nlm.nih.gov/pubmed/35098620?dopt=Abstract

Predictors of Sustained Response and Effects of Anti-CGRP Antibodies Discontinuation and Reinitiation in Resistant Chronic Migraine.

Authors

Predictors of Sustained Response and Effects of Anti-CGRP Antibodies Discontinuation and Reinitiation in Resistant Chronic Migraine.
Iannone L F, Fattori D, Benemei S, Chiarugi A, Geppetti P, De Cesaris F
Eur J Neurol. 2022 Jan 31.
PMID: 35098620.

Abstract

Guidelines for migraine prophylaxis suggest stopping medication after 6-12 months to reevaluate treatment appropriateness. The Italian Medicines Agency (AIFA) set a mandatory regulation to stop anti-CGRP (calcitonin gene related protein) pathway monoclonal antibody (anti-CGRP mAbs) treatments for 3 months after 12-months of treatment. Herein, we assess the effects of discontinuation and retreatment of anti-CGRP mAbs in resistant chronic migraine patients, evaluating predictive factors of sustained response.
Read This Paper